Last Price
0.516
Today's Change
-0.011 (2.08%)
Day's Change
0.512 - 0.53
Trading Volume
287,212
Market Cap
15 Million
Shares Outstanding
29 Million
Avg Volume
1,314,579
Avg Price (50 Days)
0.40
Avg Price (200 Days)
0.34
PE Ratio
-1.40
EPS
-0.37
Earnings Announcement
23-Oct-2024
Previous Close
0.53
Open
0.53
Day's Range
0.512 - 0.53
Year Range
0.19 - 1.58
Trading Volume
287,217
1 Day Change
-2.10%
5 Day Change
6.47%
1 Month Change
57.92%
3 Month Change
23.93%
6 Month Change
39.59%
Ytd Change
14.76%
1 Year Change
-12.47%
3 Year Change
-95.25%
5 Year Change
-84.21%
10 Year Change
-95.77%
Max Change
-99.02%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.